Nektar Therapeutics Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price
Nektar Therapeutics (NKTR) had Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price of $20.35 per share as of 2017-12-31, per its 10-K filed 2018-03-01.
Discontinued › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 · last filed 2018-03-01
- 2017-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $20.35.
- 2016-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $12.01.
- 2015-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $11.22.
- 2014-12-31: Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price $10.50.
| Period end | Share-based Payment Arrangement, Option, Exercise Price Range, Exercisable, Weighted Average Exercise Price |
|---|---|
| 2017-12-31 | $20.35 10-K · filed 2018-03-01 |
| 2016-12-31 | $12.01 10-K · filed 2017-03-01 |
| 2015-12-31 | $11.22 10-K · filed 2016-02-29 |
| 2014-12-31 | $10.50 10-K · filed 2015-02-26 |
| 2013-12-31 | $9.06 10-K · filed 2014-02-27 |
| 2012-12-31 | $9.03 10-K · filed 2013-03-01 |
| 2011-12-31 | $9.29 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Sarepta Therapeutics, Inc. (SRPT) | United States | $1.941B | -13.89 |